Professional Background
During his tenure at Novartis, Greg was pivotal in spearheading the development of drug substance and drug product processes for numerous monoclonal antibodies and therapeutic proteins. His contributions extended further as a core member of Novartis's leadership team, where he led the CMC efforts throughout the acquisition of CART19 (KYMRIAH) from the University of Pennsylvania.
Prior to joining Novartis, Greg served as Vice President and CSO at Cook Pharmica, shaping the organization for two years. Additionally, he was Vice President of Vaccine Development at Wyeth, playing an instrumental role in developing Prevnar, Prevnar 13, and CAIV (Cold Adapted Influenza Vaccine).
At Eli Lilly, Greg led the successful development and commercialization of Xigris (Activated Protein C produced in HEK293 cells) and Forteo (parathyroid hormone produced in E. coli). His impactful contributions at Chiron encompassed developing and creating multiple recombinant vaccines derived from CHO cells. Moreover, his efforts at Centocor significantly contributed to the development of the monoclonal antibodies Remicade, ReoPro, and Centoxin.
Prior to joining Novartis, Greg served as Vice President and CSO at Cook Pharmica, shaping the organization for two years. Additionally, he was Vice President of Vaccine Development at Wyeth, playing an instrumental role in developing Prevnar, Prevnar 13, and CAIV (Cold Adapted Influenza Vaccine).
At Eli Lilly, Greg led the successful development and commercialization of Xigris (Activated Protein C produced in HEK293 cells) and Forteo (parathyroid hormone produced in E. coli). His impactful contributions at Chiron encompassed developing and creating multiple recombinant vaccines derived from CHO cells. Moreover, his efforts at Centocor significantly contributed to the development of the monoclonal antibodies Remicade, ReoPro, and Centoxin.